Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy
Sponsor: Novartis Pharmaceuticals
A PHASE2 clinical study on Advanced Gastric Cancer and Gastro-esophageal Junction Cancer, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 10 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .